4338 Journal of Medicinal Chemistry, 2007, Vol. 50, No. 18
Kno¨r et al.
(7) Lenting, P. J.; van Mourik, J. A.; Mertens, K. The life cycle of
coagulation factor VIII in view of its structure and function. Blood
1998, 92, 3983-3996.
(36) Azzi, A.; De Santis, R.; Morfini, M.; Zakrzewska, K.; Musso, R.; et
al. TT virus contaminates first-generation recombinant factor VIII
concentrates. Blood 2001, 98, 2571-2573.
(37) Eriksson, R. K.; Fenge, C.; Lindner-Olson, E.; Ljungqvist, C.;
Rosenquist, J.; et al. The manufacturing process for B-domain deleted
recombinant factor VIII. Semin. Hematol. 2001, 38, 24-31.
(38) Ananyeva, N.; Khrenov, A.; Darr, F.; Summers, R.; Sarafanov, A.;
et al. Treating haemophilia A with recombinant blood factors: a
comparison. Expert Opin. Pharmacother. 2004, 5, 1061-1070.
(39) Barbara, J.; Flanagan, P. Blood transfusion risk: protecting against
the unknown. BMJ 1998, 316, 717-718.
(40) Medical and Scientific Advisory Council (MASAC) of the National
Hemophilia Foundation. MASAC recommencations concerning the
treatment of Hemophilia and other bleeeding disorders. In MASAC
Document 151, 2003; available at National Hemophilia Foundation
website.
(41) Bird, A.; Isarangkura, P.; Almagro, D.; Gonzaga, A.; Srivastava, A.
Factor concentrates for haemophilia in the developing world.
Haemophilia 1998, 4, 481-485.
(42) Cuatreca, P.; Wilchek, M.; Anfinsen, C. B. Selective enzyme
purification by affinity chromatography. Proc. Natl. Acad. Sci. U.S.A.
1968, 61, 636-643.
(43) Mejan, O.; Fert, V.; Delezay, M.; Delaage, M.; Cheballah, R.; et al.
Immunopurification of human factor VIII/vWF complex from plasma.
Thromb. Haemostasis 1988, 59, 364-371.
(44) Fass, D. N.; Knutson, G. J.; Katzmann, J. A. Monoclonal antibodies
to porcine factor VIII coagulant and their use in the isolation of active
coagulant protein. Blood 1982, 59, 594-600.
(45) Addiego, J. E.; Gomperts, E.; Liu, S. L.; Bailey, P.; Courter, S. G.;
et al. Treatment of Hemophilia-A with a highly purified factor-VIII
concentrate prepared by anti-FVIIIc immunoaffinity chromatography.
Thromb. Haemostasis 1992, 67, 19-27.
(46) Boedeker, B. G. The manufacturing of the recombinant factor VIII,
Kogenate. Transfus. Med. ReV. 1992, 6, 256-260.
(47) Gomperts, E.; Lundblad, R.; Adamson, R. The manufacturing process
of recombinant factor VIII, recombinate. Transfus. Med. ReV. 1992,
6, 247-251.
(48) Jakubik, J. J.; Vicik, S. M.; Tannatt, M. M.; Kelley, B. D. West Nile
Virus inactivation by the solvent/detergent steps of the second and
third generation manufacturing processes for B-domain deleted
recombinant factor VIII. Haemophilia 2004, 10, 69-74.
(49) Jiang, R.; Monroe, T.; McRogers, R.; Larson, P. J. Manufacturing
challenges in the commercial production of recombinant coagulation
factor VIII. Haemophilia 2002, 8, 1-5.
(50) Jack, G. W.; Beer, D. J. Immunoaffinity chromatography. Methods
Mol. Biol. 1996, 59, 187-196.
(51) Scopes, R. K. Protein Purification: Principles and Practice, 3rd ed.;
Springer: New York, 1994; p 380.
(52) Roque, A. C.; Lowe, C. R.; Taipa, M. A. Antibodies and genetically
engineered related molecules: production and purification. Biotech-
nol. Prog. 2004, 20, 639-654.
(53) Labrou, N. E. Design and selection of ligands for affinity chroma-
tography. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2003,
790, 67-78.
(54) Lowe, C. R.; Lowe, A. R.; Gupta, G. New developments in affinity
chromatography with potential application in the production of
biopharmaceuticals. J. Biochem. Biophys. Methods 2001, 49, 561-
574.
(55) Clonis, Y. D. Affinity chromatography matures as bioinformatic and
combinatorial tools develop. J. Chromatogr. A 2006, 1101, 1-24.
(56) Lowe, C. R. Combinatorial approaches to affinity chromatography.
Curr. Opin. Chem. Biol. 2001, 5, 248-256.
(57) Kelley, B. D.; Tannatt, M.; Magnusson, R.; Hagelberg, S.; Booth, J.
Development and validation of an affinity chromatography step using
a peptide ligand for cGMP production of factor VIII. Biotechnol.
Bioeng. 2004, 87, 400-412.
(58) Kelley, B. D.; Booth, J.; Tannatt, M.; Wub, Q. L.; Ladner, R.; et al.
Isolation of a peptide ligand for affinity purification of factor VIII
using phage display. J. Chromatogr. A 2004, 1038, 121-130.
(59) Amatschek, K.; Necina, R.; Hahn, R.; Schallaun, E.; Schwinn, H. et
al. Affinity chromatography of human blood coagulation factor VIII
on monoliths with peptides from a combinatorial library. J. High
Resolut. Chromatogr. 2000, 23, 47-58.
(60) Pflegerl, K.; Hahn, R.; Berger, E.; Jungbauer, A. Mutational analysis
of a blood coagulation factor VIII-binding peptide. J. Pept. Res. 2002,
59, 174-182.
(61) Gerlach, H.; Prelog, V.; Owtschinnikow, J. A. Cycloenantiomerie
und cyclodiastereomerie .2. Mitteilung u¨ber Cycloenantiomere Cyclo-
Hexaalanyle und Cycloenantiomeres Cyclo-Diglycyl-Tetraalanyl.
HelV. Chim. Acta 1964, 47, 2294-2303.
(62) Prelog, V.; Gerlach, H. Cycloenantiomerie und Cyclodiastereomerie
1. Mitteilung. HelV. Chim. Acta 1964, 47, 2288-2294.
(8) Mannucci, P. M. Hemophilia: treatment options in the twenty-first
century. J. Thromb. Haemost. 2003, 1, 1349-1355.
(9) Hoots, W. K. The future of plasma-derived clotting factor concen-
trates. Haemophilia 2001, 7, 4-9.
(10) United Kingdom Haemophilia Centre Doctors’ Organisation (UKH-
CDO). Guidelines on the selection and use of therapeutic products
to treat haemophilia and other hereditary bleeding disorders. Hae-
mophilia 2003, 9, 1-23.
(11) Bishop, P.; Lawson, J. Recombinant biologics for treatment of
bleeding disorders. Nat. ReV. Drug DiscoVery 2004, 3, 684-694.
(12) Vehar, G. A.; Keyt, B.; Eaton, D.; Rodriguez, H.; O’Brien, D. P.; et
al. Structure of human factor VIII. Nature 1984, 312, 337-342.
(13) Wang, W.; Wang, Y. J.; Kelner, D. N. Coagulation factor VIII:
structure and stability. Int. J. Pharm. 2003, 259, 1-15.
(14) Wise, R. J.; Dorner, A. J.; Krane, M.; Pittman, D. D.; Kaufman, R.
J. The role of von Willebrand factor multimers and propeptide
cleavage in binding and stabilization of factor VIII. J. Biol. Chem.
1991, 266, 21948-21955.
(15) Saenko, E. L.; Scandella, D. The acidic region of the factor VIII
light chain and the C2 domain together form the high affinity binding
site for von Willebrand factor. J. Biol. Chem. 1997, 272, 18007-
18014.
(16) Fay, P. J.; Coumans, J. V.; Walker, F. J. von Willebrand factor
mediates protection of factor VIII from activated protein C-catalyzed
inactivation. J. Biol. Chem. 1991, 266, 2172-2177.
(17) Nesheim, M.; Pittman, D. D.; Giles, A. R.; Fass, D. N.; Wang, J.
H.; et al. The effect of plasma von Willebrand factor on the binding
of human factor VIII to thrombin-activated human platelets. J. Biol.
Chem. 1991, 266, 17815-17820.
(18) Koppelman, S. J.; Koedam, J. A.; Vanwijnen, M.; Stern, D. M.;
Nawroth, P. P.; et al. Von Willebrand factor as a regulator of intrinsic
factor X activation. J. Lab. Clin. Med. 1994, 123, 585-593.
(19) Toole, J. J.; Pittman, D. D.; Orr, E. C.; Murtha, P.; Wasley, L. C.; et
al. A large region (approximately equal to 95 kDa) of human factor
VIII is dispensable for in vitro procoagulant activity. Proc. Natl. Acad.
Sci. U.S.A. 1986, 83, 5939-5942.
(20) Khrenov, A. V.; Ananyeva, N. M.; Saenko, E. L. Role of the B
domain in proteolytic inactivation of activated coagulation factor VIII
by activated protein C and activated factor X. Blood Coagulation
Fibrinolysis 2006, 17, 379-388.
(21) Fay, P. J.; Anderson, M. T.; Chavin, S. I.; Marder, V. J. The size of
human factor VIII heterodimers and the effects produced by thrombin.
Biochim. Biophys. Acta 1986, 871, 268-278.
(22) Fay, P. J. Activation of factor VIII and mechanisms of cofactor action.
Blood ReV. 2004, 18, 1-15.
(23) Stoylova, S. S.; Lenting, P. J.; Kemball-Cook, G.; Holzenburg, A.
Electron crystallography of human blood coagulation factor VIII
bound to phospholipid monolayers. J. Biol. Chem. 1999, 274, 36573-
36578.
(24) Farrugia, A. Safety and supply of haemophilia products: worldwide
perspectives. Haemophilia 2004, 10, 327-333.
(25) Mannucci, P. M. Treatment of hemophilia: recombinant factors only?
No. J. Thromb. Haemostasis 2003, 1, 216-217.
(26) Hoots, W. K. Safety issues affecting hemophilia products. Transfus.
Med. ReV. 2001, 15, 11-19.
(27) Hoots, W. K. History of plasma-product safety. Transfus. Med. ReV.
2001, 15, 3-10.
(28) Gitschier, J.; Wood, W. I.; Goralka, T. M.; Wion, K. L.; Chen, E.
Y.; et al. Characterization of the human factor-VIII gene. Nature
1984, 312, 326-330.
(29) Wood, W. I.; Capon, D. J.; Simonsen, C. C.; Eaton, D. L.; Gitschier,
J.; et al. Expression of active human factor VIII from recombinant
DNA clones. Nature 1984, 312, 330-337.
(30) Toole, J. J.; Knopf, J. L.; Wozney, J. M.; Sultzman, L. A.; Buecker,
J. L.; et al. Molecular cloning of a cDNA encoding human
antihaemophilic factor. Nature 1984, 312, 342-347.
(31) Kaufman, R. J.; Pipe, S. W. Can we improve on nature? “Super
molecules” of factor VIII. Haemophilia 1998, 4, 370-379.
(32) Saenko, E. L.; Ananyeva, N. M.; Shima, M.; Hauser, C. A.; Pipe, S.
W. The future of recombinant coagulation factors. J. Thromb.
Haemostasis 2003, 1, 922-930.
(33) Lee, C. Recombinant clotting factors in the treatment of hemophilia.
Thromb. Haemostasis 1999, 82, 516-524.
(34) Pipe, S. W.; Saint-Remy, J. M.; Walsh, C. E. New high-technology
products for the treatment of haemophilia. Haemophilia 2004, 10,
55-63.
(35) Betts, J. P. Recombinant factor VIII may not abolish risk of new
variant CJD from factor VIII. BMJ 1998, 316, 1385.